TEL : 028-85121781
Set Homepage | Add Favorite     中文 | English

For more than 20 years since its establishment, Jiuzhang Biotech has been committed to the development of such projects as “the research and development of national class I and II new anti-tumor drugs with independent intellectual property” and “the development of natural plant-based healthcare food by incorporating the nanotechnology”, and has invested hundreds of millions of scientific research funds in succession. During the process, Jiuzhang Biotech has reaped many honors, among which the honors obtained in the past three years are as follow:

In 2016

Phase I/II Clinical Study of Chlorogenic Acid for Injection, the Class I of the New Medicines had been listed by National Health and Family Planning Commission of  PRC and Ministry of Science and Technology of the People's Republic of China in the National 13th-five-year plan Science and Technology Major Special Major New Drug Creation Project;

Nature, as the world famous science journal, had conducted an exclusive interview to Mr. Zhang Jie, the inventor of chlorogenic acid, Professor Chen Xiaoguang from the Institute of Materia Medica, China Academy of Medical Sciences, the study director of the anti-tumor mechanism research, and Professor Li Wenbin from the Department of Brain Glioma at the Beijing Shijitan Hospital (currently in the Beijing Tiantan Hospital affiliated to the Capital Medical University), the principal investigator of the glioma clinical trial in the “1st Pharmaceutical Investment and Innovation Conference”, and had published the interview content in the English version of Nature issued on December 22, 2016, entitled as New Breakthrough in Antitumor Drug.

In 2017

“Phase II clinical study on the treatment of glioma with chlorogenic acid for injection, class I of the innovative natural small molecule immune drug” was appraised as “a major special project in Sichuan Province” by Sichuan Science and Technology Department;

Scientific Reports, a journal of Nature, published an article entitled Chlorogenic Acid Inhibits Glioblastoma Growth through Repolarizating Macrophage from M2 to M1 Phenotype, which elaborated and demonstrated the mechanism of chlorogenic acid for injection promoting apoptosis and inhibiting growth of malignant tumors. Great external repercussions have been achieved. 

In 2018

Research and Development of Chlorogenic Acid for Injection (Phase Ib Clinical Study of Advanced Lung Cancer) obtained the Directional Financial Transfer Payment Project in Sichuan Province.